## **Core Concept**
Reslizumab is a medication used in the management of severe asthma. It targets a specific pathway involved in the pathogenesis of asthma. Understanding its mechanism of action is crucial for its clinical application.

## **Why the Correct Answer is Right**
Reslizumab is a monoclonal antibody that targets **interleukin-5 (IL-5)**. IL-5 is a cytokine that plays a critical role in the growth and differentiation, survival, and activation of eosinophils, which are a type of white blood cell involved in the inflammation seen in asthma. By inhibiting IL-5, reslizumab effectively reduces eosinophilic inflammation in the airways, which is particularly beneficial for patients with severe asthma characterized by eosinophilic inflammation.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, although several monoclonal antibodies target various pathways in asthma, the specific target of reslizumab is not listed here.
- **Option B:** This option is incorrect as it does not accurately represent the target of reslizumab.
- **Option D:** This option is incorrect because it also does not accurately represent the target of reslizumab.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that reslizumab is specifically indicated for patients with severe asthma and evidence of eosinophilic inflammation (e.g., elevated levels of eosinophils). It is not used for all types of asthma, making it essential to identify the right patient population for this therapy.

## **Correct Answer:** .